Companies › Acer Therapeutics
1 active drug program in 1 registered trial: 1 Phase 3; Other; next expected readout Mar 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Celiprolol (ACER-002) Beta-2 adrenergic receptor partial agonist; Adrenergic receptor alpha-2 antagonist; Beta-1 adrenergic receptor antagonist | ADRB2, ADRA2A, ADRA2C, ADRA2B, ADRB1 | Phase 3 | Vascular Ehlers-Danlos Syndrome | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05432466 | Celiprolol (ACER-002) | Phase 3 | Vascular Ehlers-Danlos Syndrome | Other | Mar 2029 |
ARS Pharmaceuticals Chiesi Farmaceutici AstraZeneca Guangzhou Novaken Pharm BioXcel Therapeutics Teikoku Pharma USA Tarian Pharma Alcon Research Actimed Therapeutics GSK
Shanghai Haiyan Pharmaceutical Technology Kaken Pharmaceutical Spine BioPharma Vertanical NTC srl
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.